Obstet Gynecol Sci.  2015 Sep;58(5):368-376. 10.5468/ogs.2015.58.5.368.

The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients

• Ryu HK
• Baek JS
• Kang WD
• Kim SM

• KMID: 2058460
• DOI: http://doi.org/10.5468/ogs.2015.58.5.368

Abstract

OBJECTIVE
The aim of this study was to evaluate the prognostic value of squamous cell carcinoma antigen (SCC-Ag) and the optimal cut-off value for predicting recurrence in cervical squamous cell carcinoma patients with complete remission after primary treatment.
METHODS
We reviewed the records of 783 cervical squamous cell cancer patients who underwent primary therapy and showed complete remission at our institution between January 2000 and April 2014. A receiver operating characteristic curve was used to determine the optimal SCC-Ag threshold to predict recurrence. Cox regression model for disease free survival was used to assess differences in outcome.
RESULTS
The median follow-up period was 41.2 months, and 154 patients (19.7%) had recurrent disease. The median pretreatment and posttreatment SCC-Ag level was 2.6 ng/mL (range, 0.1 to 532.0 ng/mL) and 0.7 ng/mL (range, 0.0 to 46.8 ng/mL), respectively. Both pretreatment and posttreatment SCC-Ag levels were higher in the recurrence group (P=0.017 and P=0.039). Optimal cut-off value of pretreatment and posttreatment SCC-Ag for predicting recurrence was 1.86 ng/mL (area under the curve, 0.663; P=0.000), and 0.9 ng/mL (area under the curve, 0.581; P=0.002), respectively. In the multivariate Cox regression model, pretreatment SCC-Ag >1.86 ng/mL (odds ratio, 2.11; 95% confidence interval, 1.38 to 3.22; P=0.001) and posttreatment SCC-Ag >0.9 ng/mL (odds ratio, 1.64; 95% confidence interval, 1.18 to 2.28; P=0.003) were significantly associated with poor disease free survival.
CONCLUSION
Patients with pretreatment SCC-Ag >1.86 ng/mL or posttreatment SCC-Ag >0.9 ng/mL should be considered at high risk for cancer recurrence after complete remission, and therefore, closer surveillance is needed.

Keyword

Cervical squamous cell cancer; Cut-off value; Disease-free survival; Squamous cell carcinoma-related antigen

MeSH Terms

Carcinoma, Squamous Cell*
Disease-Free Survival
Follow-Up Studies
Humans
Neoplasms, Squamous Cell
Recurrence*
ROC Curve

Figure

• 

  Fig. 1 Receiver operating characteristic curve for pretreatment squamous cell carcinoma antigen (SCC-Ag) level (A), and posttreatment SCC-Ag level (B) for predicting recurrence. Optimal cut-off value of pretreatment and posttreatment SCC-Ag for predicting tumor recurrence was 1.86 and 0.9 ng/mL, respectively. AUC, area under the curve; CI, confidence interval.

• 

  Fig. 2 Disease free survival depending on the pretreatment (A) and posttreatment (B) squamous cell carcinoma antigen (SCC-Ag) level, tumor size (C), lymph node involvement (D).

Reference

1. American Cancer Society. Global cancer facts & figures 3rd edition [Internet]. Atlanta (GA): American Cancer Society;c2015. cited 2015 Feb 20. Available from: http://www.cancer.org/research/cancerfactsstatistics.

2. Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res. 1997; 17:2329–2334.

3. Esajas MD, Duk JM, de Bruijn HW, Aalders JG, Willemse PH, Sluiter W, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol. 2001; 19:3960–3966.

4. Avall-Lundqvist EH, Sjovall K, Nilsson BR, Eneroth PH. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer. 1992; 28A:1695–1702.

5. Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG, et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol. 1996; 14:111–118.

6. Yuan CC, Wang PH, Ng HT, Tsai LC, Juang CM, Chiu LM. Both TPA and SCC-Ag levels are prognostic even in highrisk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. Eur J Gynaecol Oncol. 2002; 23:17–20.

7. Strauss HG, Laban C, Lautenschlager C, Buchmann J, Schneider I, Koelbl H. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer. 2002; 38:1987–1991.

8. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torne A, Rovirosa A, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 2003; 24:156–164.

9. Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol. 2005; 23:1455–1462.

10. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis. Gynecol Oncol. 2000; 77:164–170.

11. Scambia G, Panici PB, Baiocchi G, Amoroso M, Foti E, Greggi S, et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol. 1991; 164:631–636.

12. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2000; 20:5113–5115.

13. Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol. 2002; 100:781–787.

14. Maiman M. The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol. 2002; 84:4–6.

15. Gadducci A, Tana R, Fanucchi A, Genazzani AR. Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol. 2007; 107:1 Suppl 1. S23–S26.

16. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008; 66:10–20.

17. Abe A, Nakano T, Morita S, Oka K. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer. Anticancer Res. 1999; 19:829–836.

18. Bolger BS, Dabbas M, Lopes A, Monaghan JM. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol. 1997; 65:309–313.

19. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 19981; 41:823–830.

20. Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology. 1991; 180:319–322.

21. Nicolet V, Carignan L, Bourdon F, Prosmanne O. MR imaging of cervical carcinoma: a practical staging approach. Radiographics. 2000; 20:1539–1549.

22. Miller C, Elkas JC. Cervical and vaginal cancer. In : Berek JS, editor. Berek & Novak's gynecology. 15th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2012. p. 1304–1349.

23. Montag TW. Tumor markers in gynecologic oncology. Obstet Gynecol Surv. 1990; 45:94–105.

24. Duk JM, de Bruijn HW, Groenier KH, Hollema H, ten Hoor KA, Krans M, et al. Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol. 1990; 39:186–194.

25. de Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H, et al. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol. 1998; 19:505–516.

26. Davelaar EM, van de Lande J, von Mensdorff-Pouilly S, Blankenstein MA, Verheijen RH, Kenemans P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumour Biol. 2008; 29:9–17.

27. Gadducci A, Scambia G, Panici PB, Ferdeghini M, Battaglia F, Caenaro G, et al. The prognostic relevance of pretreatment serum immunosuppressive acidic protein (IAP) in patients with squamous cell carcinoma of the uterine cervix: a comparison with squamous cell carcinoma antigen (SCC). Cancer J. 1994; 7:241–247.

28. Boss EA, Barentsz JO, Massuger LF, Boonstra H. The role of MR imaging in invasive cervical carcinoma. Eur Radiol. 2000; 10:256–270.

29. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518–527.

30. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006; 208:152–164.

31. de Cremoux P, de la Rochefordiere A, Savignoni A, Kirova Y, Alran S, Fourchotte V, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer. 2009; 124:778–782.

32. Lai CH, Chang CJ, Huang HJ, Hsueh S, Chao A, Yang JE, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol. 2007; 25:3628–3634.

33. Schwartz SM, Daling JR, Shera KA, Madeleine MM, McKnight B, Galloway DA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001; 19:1906–1915.